Yahoo
NYSE - Delayed Quote USD

CONMED Corporation (CNMD)

33.83 +1.07 (+3.27%)
At close: July 2 at 4:00:02 PM EDT
33.83 0.00 (0.00%)
After hours: July 2 at 5:05:00 PM EDT
Trade CONMED on Coinbase
Chart Range Bar
Loading chart for CNMD
  • Previous Close 32.76
  • Open 33.31
  • Bid 31.45 x 40000
  • Ask 34.97 x 40000
  • Day's Range 32.98 - 34.08
  • 52 Week Range 31.44 - 56.64
  • Volume 360,160
  • Avg. Volume 496,801
  • Market Cap (intraday) 1.019B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) 19.11
  • EPS (TTM) 1.77
  • Earnings Date Jul 29, 2026
  • Forward Dividend & Yield 0.80 (2.36%)
  • Ex-Dividend Date Sep 15, 2025
  • 1y Target Est 39.60

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

www.conmed.com

3,900

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 7/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNMD
16.67%
S&P 500 (^GSPC)
9.32%

1-Year Return

CNMD
37.37%
S&P 500 (^GSPC)
20.17%

3-Year Return

CNMD
74.47%
S&P 500 (^GSPC)
68.15%

5-Year Return

CNMD
74.65%
S&P 500 (^GSPC)
71.94%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 317.05M
Earnings 27.1M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
100M
200M
300M

Analyst Insights

View More

Analyst Price Targets

39.00
39.60 Average
33.83 Current
40.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/29/2026
Analyst B of A Securities
Rating Action Downgrade
Rating Underperform
Price Action Maintains
Price Target 40 -> 40

Statistics

View More

Valuation Measures

Annual
As of 7/1/2026
  • Market Cap

    986.38M

  • Enterprise Value

    1.81B

  • Trailing P/E

    18.51

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.74

  • Price/Book (mrq)

    0.97

  • Enterprise Value/Revenue

    1.32

  • Enterprise Value/EBITDA

    9.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.00%

  • Return on Assets (ttm)

    3.76%

  • Return on Equity (ttm)

    5.50%

  • Revenue (ttm)

    1.37B

  • Net Income Avi to Common (ttm)

    54.85M

  • Diluted EPS (ttm)

    1.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    35.03M

  • Total Debt/Equity (mrq)

    84.59%

  • Levered Free Cash Flow (ttm)

    127.06M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

33.83 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • CONMED CORP has an Investment Rating of HOLD; a target price of $31.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    CONMED CORP has an Investment Rating of HOLD; a target price of $31.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
  • CONMED CORP has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    CONMED CORP has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
  • CONMED CORP has an Investment Rating of HOLD; a target price of $33.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    CONMED CORP has an Investment Rating of HOLD; a target price of $33.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
  • CONMED CORP has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    CONMED CORP has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: